^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ramantamig (JNJ-5322)

    i
    Other names: JNJ 5322, JNJ 79635322, JNJ-5322, JNJ-79635322, JNJ5322, JNJ79635322
    Company:
    J&J
    Drug class:
    CD3 agonist, BCMA inhibitor, GPRC5D inhibitor
    Related drugs:
    3d
    TRIlogy-7: A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • ramantamig (JNJ-5322) • dexamethasone injection
    22d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    1m
    79635322MMY2001: A Phase 2 Study of JNJ-79635322 in Participants with RRMM (2025-521976-80-00)
    P1/2, N=28, Not yet recruiting, Janssen Cilag International
    New P1/2 trial
    |
    ramantamig (JNJ-5322)
    1m
    TRI Pro: A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=230, Not yet recruiting, Janssen Research & Development, LLC
    New P2 trial
    |
    Actemra IV (tocilizumab) • ramantamig (JNJ-5322)
    2ms
    Talisman: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (clinicaltrials.gov)
    P2, N=210, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2029 --> May 2030 | Trial primary completion date: Apr 2026 --> May 2030
    Trial completion date • Trial primary completion date
    |
    ramantamig (JNJ-5322) • Talvey (talquetamab-tgvs)
    3ms
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    4ms
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=157, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ramantamig (JNJ-5322)
    4ms
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2028 --> Nov 2028
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • ramantamig (JNJ-5322)
    5ms
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    6ms
    CR109234: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Aug 2028
    Trial completion date • First-in-human
    |
    ramantamig (JNJ-5322)
    6ms
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2028 --> Nov 2027
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • ramantamig (JNJ-5322)
    6ms
    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Heidelberg Medical Center | Trial completion date: Aug 2028 --> Sep 2029 | Trial primary completion date: Feb 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • ramantamig (JNJ-5322) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)